Prelude Therapeutics Management
Management criteria checks 3/4
Prelude Therapeutics' CEO is Kris Vaddi, appointed in Feb 2016, has a tenure of 8.83 years. total yearly compensation is $2.64M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 3.93% of the company’s shares, worth $2.81M. The average tenure of the management team and the board of directors is 3 years and 4.6 years respectively.
Key information
Kris Vaddi
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 21.7% |
| CEO tenure | 8.8yrs |
| CEO ownership | 3.9% |
| Management average tenure | 3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$573k | -US$122m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$117m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$558k | -US$115m |
| Sep 30 2022 | n/a | n/a | -US$120m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$7m | US$544k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$12m | US$417k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$315k | -US$28m |
Compensation vs Market: Kris's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD654.40K).
Compensation vs Earnings: Kris's compensation has been consistent with company performance over the past year.
CEO
Kris Vaddi (58 yo)
8.8yrs
Tenure
US$2,641,789
Compensation
Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.8yrs | US$2.64m | 3.93% $ 2.8m | |
| President & Chief Medical Officer | 2.7yrs | US$1.65m | 0.12% $ 82.3k | |
| Interim CFO | 1.9yrs | US$1.67m | 0.0044% $ 3.1k | |
| Senior VP and Head of Strategic Planning & Operations | 2.9yrs | no data | no data | |
| Senior Vice President of Technical Operations | 3.9yrs | no data | no data | |
| Chief Scientific Officer | 6.7yrs | US$1.63m | 0.33% $ 234.9k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief People Officer | 3.5yrs | no data | no data | |
| Executive VP & Chief Chemistry Officer | 5.7yrs | US$2.63m | 0.57% $ 405.7k | |
| Senior Vice President of Translation Medicine | 3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.2yrs | no data | no data |
3.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: PRLD's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.8yrs | US$2.64m | 3.93% $ 2.8m | |
| Independent Director | 3.9yrs | US$140.03k | 0% $ 0 | |
| Independent Chairman of the Board | 8.4yrs | US$161.03k | 0.91% $ 650.1k | |
| Independent Director | 3.4yrs | US$134.53k | 0% $ 0 | |
| Independent Director | 8.4yrs | US$144.53k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$147.03k | 0.018% $ 13.0k | |
| Independent Director | 4.6yrs | US$131.03k | 0% $ 0 |
4.6yrs
Average Tenure
58yo
Average Age
Experienced Board: PRLD's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prelude Therapeutics Incorporated is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Graig Suvannavejh | Goldman Sachs |